Literature DB >> 11021827

Induction of vascular adhesion protein-1 during liver allograft rejection and concomitant cytomegalovirus infection in rats.

T Martelius1, M Salmi, H Wu, C Bruggeman, K Höckerstedt, S Jalkanen, I Lautenschlager.   

Abstract

Vascular adhesion protein-1 (VAP-1) is an adhesion molecule controlling lymphocyte recirculation through high endothelial venules of the lymph nodes. It has also been shown to be induced and to mediate lymphocyte adhesion at sites of inflammation. We studied the expression of VAP-1 and two other inducible adhesion molecules ICAM-1 and VCAM-1 in our experimental model of rat liver allograft rejection and, in addition, the effect of concomitant rat cytomegalovirus (RCMV) infection on this expression. Expression of VAP-1, ICAM-1, and VCAM-1 was studied in rat liver allografts with or without RCMV infection, isografts, and normal rat liver. Immunoperoxidase technique and monoclonal antibodies including a novel anti-VAP-1 reagent were used. VAP-1 expression was induced by acute rejection in sinusoids, hepatocytes, and also in bile ducts, when compared to the isografts or normal liver, where only blood vessels were consistently positive. Sinusoidal and hepatocyte expression of VAP-1 was prolonged by the presence of RCMV. ICAM-1 and VCAM-1 expression was also induced by acute rejection. However, RCMV increased sinusoidal VCAM-1 expression compared to uninfected grafts. The present experimental study shows that VAP-1 is up-regulated in acute rejection of liver allografts, and that this up-regulation is prolonged by RCMV infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11021827      PMCID: PMC1850156          DOI: 10.1016/S0002-9440(10)64638-X

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  Increased expression of interleukin-6 and tumor necrosis factor-alpha in pathologic biliary epithelial cells: in situ and culture study.

Authors:  M Yasoshima; N Kono; H Sugawara; K Katayanagi; K Harada; Y Nakanuma
Journal:  Lab Invest       Date:  1998-01       Impact factor: 5.662

Review 2.  Cell adhesion and migration. IV. Lymphocyte trafficking in the intestine and liver.

Authors:  M Salmi; D Adams; S Jalkanen
Journal:  Am J Physiol       Date:  1998-01

3.  Persistent cytomegalovirus in liver allografts with chronic rejection.

Authors:  I Lautenschlager; K Höckerstedt; H Jalanko; R Loginov; K Salmela; E Taskinen; J Ahonen
Journal:  Hepatology       Date:  1997-01       Impact factor: 17.425

4.  A rat model of monitoring liver allograft rejection.

Authors:  T Martelius; H Mäkisalo; K Höckerstedt; E Taskinen; I Lautenschlager
Journal:  Transpl Int       Date:  1997       Impact factor: 3.782

5.  Cytomegalovirus infection is associated with increased inflammation and severe bile duct damage in rat liver allografts.

Authors:  T Martelius; L Krogerus; K Höckerstedt; C Bruggeman; I Lautenschlager
Journal:  Hepatology       Date:  1998-04       Impact factor: 17.425

6.  Expression of adhesion molecules and their ligands in liver allografts during cytomegalovirus (CMV) infection and acute rejection.

Authors:  I Lautenschlager; K Höckerstedt; E Taskinen; E von Willebrand
Journal:  Transpl Int       Date:  1996       Impact factor: 3.782

7.  Different forms of human vascular adhesion protein-1 (VAP-1) in blood vessels in vivo and in cultured endothelial cells: implications for lymphocyte-endothelial cell adhesion models.

Authors:  M Salmi; S Jalkanen
Journal:  Eur J Immunol       Date:  1995-10       Impact factor: 5.532

8.  Vascular adhesion protein 1 mediates binding of T cells to human hepatic endothelium.

Authors:  G McNab; J L Reeves; M Salmi; S Hubscher; S Jalkanen; D H Adams
Journal:  Gastroenterology       Date:  1996-02       Impact factor: 22.682

9.  Organ-selective regulation of vascular adhesion protein-1 expression in man.

Authors:  A M Arvilommi; M Salmi; S Jalkanen
Journal:  Eur J Immunol       Date:  1997-07       Impact factor: 5.532

10.  Vascular adhesion protein 1 (VAP-1) mediates lymphocyte subtype-specific, selectin-independent recognition of vascular endothelium in human lymph nodes.

Authors:  M Salmi; S Tohka; E L Berg; E C Butcher; S Jalkanen
Journal:  J Exp Med       Date:  1997-08-18       Impact factor: 14.307

View more
  7 in total

1.  The role of sICAM-1 detection in the diagnosis of acute rejection following liver transplantation.

Authors:  Yahong Yu; Zhong Chen; Qifa Ye
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

Review 2.  Infections after orthotopic liver transplantation.

Authors:  Mark Pedersen; Anil Seetharam
Journal:  J Clin Exp Hepatol       Date:  2014-07-24

3.  Expression of vascular adhesion protein-1 in normal and inflamed mice lungs and normal human lungs.

Authors:  Baljit Singh; Thomas Tschernig; Martijn van Griensven; Armin Fieguth; Reinhard Pabst
Journal:  Virchows Arch       Date:  2003-04-17       Impact factor: 4.064

4.  Blockade of vascular adhesion protein-1 inhibits lymphocyte infiltration in rat liver allograft rejection.

Authors:  Timi Martelius; Ville Salaspuro; Marko Salmi; Leena Krogerus; Krister Höckerstedt; Sirpa Jalkanen; Irmeli Lautenschlager
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

Review 5.  Cytomegalovirus and chronic allograft rejection in liver transplantation.

Authors:  Liang-Hui Gao; Shu-Sen Zheng
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

6.  Vascular adhesion protein-1 blockade suppresses choroidal neovascularization.

Authors:  Kousuke Noda; Haicheng She; Toru Nakazawa; Toshio Hisatomi; Shintaro Nakao; Lama Almulki; Souska Zandi; Shinsuke Miyahara; Yasuhiro Ito; Kennard L Thomas; Rebecca C Garland; Joan W Miller; Evangelos S Gragoudas; Yukihiko Mashima; Ali Hafezi-Moghadam
Journal:  FASEB J       Date:  2008-04-24       Impact factor: 5.191

7.  Hypoxia serves a key function in the upregulated expression of vascular adhesion protein‑1 in vitro and in a rat model of hemorrhagic shock.

Authors:  Yuxing Zhang; Wei Yi; Jun Yao; Xiaojun Yu; Cheng Qian; Zhiqian Hu
Journal:  Mol Med Rep       Date:  2017-06-08       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.